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ABSTRACT
Aim: To evaluate the effects of montelukast in smoke-
induced lung injury. 
Methods: 28 Wistar-Albino rats were enrolled into 4 groups
with 7 rats per group. The healthy control group was exposed
to fresh air while all rats in the 3 experimental groups were
exposed to cigarette smoke for 20 weeks for 2 hours per day.
After histopathological verification of smoke induced lung
injury, montelukast (0.1 mg/kg) dissolved in Na2CO3 was
given in one group (MON), Na2CO3 only was given in another
group (MON control) and placebo was injected in the third
group (COPD control) intraperitoneally for 21 days. At the
end of this period blood samples were obtained for serum
TNF-α assessment and light and electron microscopy analy-
ses were performed on the lung tissues of sacrificed rats.
Results: Serum TNF-α levels in the MON group were signifi-
cantly lower than in the MON control and COPD control
groups (38.84 ± 4.9 pg/ml, 77.5 ± 5.8 pg/ml and 79.2 ± 6.9
pg/ml respectively, p < 0.05). Furthermore there was no sta-
tistically significant difference between the MON group and
healthy controls with respect to serum TNF-α levels (38.84 ±
4.9 pg/ml vs. 29.5 ± 3.6 pg/ml, p > 0.05). Light and electron
microscopic evaluation of the lungs demonstrated that the
total histopathological damage score of the lung samples was
significantly lower in the MON group than in MON controls
and COPD controls (5.14 ± 0.5, 8.4 ± 0.6 and 8.7 ± 0.4 respec-
tively, p < 0.05), while there was no significant difference
between the MON group and healthy controls (5.1 ± 0.6 vs
2.3 ± 0.2, p > 0.05). 
Conclusion: These findings suggest that montelukast might
have a protective effect on smoke-induced lung injury in rats
both from a histopathological and inflammatory point of
view. 
Keywords: Chronic bronchitis, inflammation, montelukast,
smoking.
RIASSUNTO 
Scopo: Valutare gli effetti del montelukast sui danni polmo-
nari indotti dal fumo. 
Metodi: 28 ratti Wistar-Albino sono stati suddivisi in 4 gruppi
di 7 ratti per gruppo. Il gruppo di controlli normali è stato
esposto ad aria pura, mentre tutti i ratti dei 3 gruppi speri-
mentali sono stati esposti a fumo di sigaretta per 20 settima-
ne per 2 ore al giorno. Dopo la verifica istopatologica del dan-
no polmonare indotto da fumo ad un gruppo è stato sommi-
nistrato montelukast (0,1 mg/kg) disciolto in Na2CO3 (MON),
ad un altro gruppo è stato somministrato il solo Na2CO3 (con-
trolli MON) e nel terzo gruppo è stato iniettato placebo (con-
trolli COPD) per via intraperitoneale per 21 giorni. Al termine
di questo periodo sono stati effettuati prelievi di sangue per
il dosaggio del TNF-α serico e sul tessuto polmonare dei ratti
sacrificati sono state effettuate analisi al microscopio ottico
ed elettronico.
Risultati: I livelli serici di TNF-α nel gruppo MON erano signi-
ficativamente inferiori ai controlli MON e ai controlli COPD
(38,84 ± 4,9 pg/ml, 77,5 ± 5,8 pg/ml e 79,2 ± 6,9 pg/ml rispet-
tivamente; p < 0,05). non vi erano inoltre differenze statisti-
camente significative tra il gruppo MON ed i controlli sani nei
livelli serici di TNF-α (38,84 ± 4,9 pg/ml vs. 29,5 ± 3,6 pg/ml,
p > 0,05). La valutazione al microscopio ottico ed elettronico
dei tessuti polmonari dimostravano che lo score complessivo
di danno istopatologico dei campioni di polmone era signifi-
cativamente minore nel gruppo MON rispetto ai controlli
MON e ai controlli COPD (5,14 ± 0,5, 8,4 ± 0,6 and 8,7 ± 0,4
rispettivamente, p < 0,05), mentre non vi erano differenze si-
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gnificative tra il gruppo MON ed i controlli sani (5,1 ± 0,6 vs
2,3 ± 0,2; p > 0,05). 
Conclusioni: Questi risultati suggeriscono che il montelukast
possa avere un effetto protettivo sul danno polmonare indot-
to da fumo nei ratti sia dal punto di vista istopatologico che
da quello infiammatorio. 
Parole chiave: Bronchite cronica, fumo, infiammazione, mon-
telukast.
BACKGROUND
Cigarette smoking induces an abnormal inflamma-
tory response in the airways which is now increas-
ingly acknowledged in the pathogenesis of chronic
obstructive pulmonary disease (COPD) [1].
Smoking classically causes neutrophil predominant
inflammation in the airways with the increase of
neutrophil chemotactic cytokines such as tumor
necrosis factor (TNF)-α, interleukin (IL)-8, and
leukotriene (LT)B4 [2-4]. 
Leukotrienes are generated from the metabolism of
arachidonic acid and have significant effects on
bronchoconstriction, mucus hypersecretion and air-
way inflammation [4]. Montelukast is a cysteinyl
leukotriene receptor antagonist (LTRA) and widely
used as an anti-inflammatory agent in the treatment
of asthma [5-7]. Recent studies conducted in smok-
er and non-smoker asthmatics have shown that in-
haled beclomethasone increased forced expiratory
volume in 1 sec (FEV1) levels only in non-smoker
asthmatics; on the other hand montelukast in-
creased morning peak flow values only in smoker
asthmatics [8]. These data suggested that smoke-in-
duced lung injury might be resistant to inhaled
steroids and that LTRA may have possible effects in
this setting. 
The bronchodilator effects of LTRA in patients with
COPD has previously been demonstrated [9,10]. In
a recent meta-analysis, Nguyen et al. reviewed 4
placebo-controlled trials investigating the effects of
LTRA in the treatment of COPD and concluded that
LTRA is associated with significant improvements in
FEV1 levels [11]. The anti-inflammatory effect of
montelukast has mostly been investigated in animal
models of asthma; therefore data is limited about its
effects on smoke-induced inflammation [12,13].
However possible protective effects on smoke-in-
duced lung injury have been previously reported
[14].
In this study, our aim was to investigate the possible
anti-inflammatory effects of montelukast in rats with
smoke-induced chronic bronchitis. Serum TNF-α
level was used as a marker of inflammation and a
histopathological evaluation of the lung was per-
formed with both light and electron microscopy. 
METHODS
Animals
Male Wistar-Albino rats, weighing 250-300 g, were
used in this study (n = 28). The rats were kept under
standard conditions (stainless-steel cages, 18-21oC,
55-60% relative humidity, and 12 hours light/dark
cycles). Standard chow in tablet form and water
were available ad libitum. All animals were free
from infections.
Rats were exposed to passive cigarette smoke for 20
weeks in order to develop COPD [15] and were de-
capitated 24 hours after the last injection of the
agents; 4 ml of blood was taken intra-cordially for
the measurement of serum TNF-α levels. Rat lung
tissues were dissected after intra cardiac perfusion. 
The present study was performed in accordance
with the Guiding Principles for the Care and Use of
Laboratory Animals; all procedures were approved
by the ethics committee of Kocaeli University.
Smoke exposure machine 
A special smoke exposure machine based on
Chen’s definition and Walton’s modification was
prepared in the Experimental Medicine Research
Laboratory of Kocaeli University [16]. Briefly, the
machine consisted of three separate chambers con-
nected to each other. The first chamber was a gen-
eration chamber where smoke was generated, the
second was a residence chamber where smoke was
diluted and the third was an exposure chamber
where rats were exposed to smoke. Fans between
the chambers were used to conduct smoke from
one chamber to another, operating at a speed of 5.2
L/min. Standardized nicotine and cigarette tar were
used for exposure 2 hours per day for 20 weeks.
Study population 
The rats were divided into four groups; smoke expo-
sure and injections were performed in three of the
groups while the group of rats without smoke expo-
sure constituted the healthy controls. All injections
were performed each day at 09:00 am after develop-
ment of COPD and continued for 21 days. The
study groups and doses of injections were as fol-
lows: 
1. MON group: 7 rats received 0.1 mg/kg mon-
telukast (Sigma-Aldrich, Italy) dissolved in 1 ml
Na2CO3 (sodium bicarbonate) intraperitoneally.
2. MON control: 7 rats received 1 ml Na2CO3
(Sigma-Aldrich, Italy) intraperitoneally (control
group for montelukast).
3. COPD control: 7 rats received 1 ml physiological
serum intraperitoneally.
4. Healthy control: the 7 rats in this group were not
exposed to smoke; however they were kept in the
same machine for 2 hours daily with clean air in
order to provide exposure to similar stress.
Histopathological evaluation 
Light microscopy: After the perfusion of 2.5% glu-
taraldehyde, lung tissue specimens were dehydrat-
ed in a graded series of ethanol (70%, 80%, 90%
and 100%), cleared in toluene and embedded in
paraffin. Section paraffin blocks at 5 µm thickness
were stained with hematoxylin and eosin (H&E) and
evaluated with an Olympus BH2 photomicroscope
(Tokyo, Japan).





























8 histopathological categories; 1) dilatation of respi-
ratory tract, 2) infiltration of inflammatory cells, 3)
proliferation of respiratory epithelium, and 4) vas-
cular congestion. The first three categories were
scored from 0 to 3, 0 indicating no pathology and 3
the most severe damage, using a semi-quantitative
scale; the last category was scored from 0 to 1 with
respect to absence or presence of vascular conges-
tion. The total histopathological score of the lung
was calculated as the sum of the scores given for
each criterion [17]. 
Electron microscopic evaluation: After the perfu-
sion of 2.5% glutaraldehyde, lung tissue specimens
were post-fixated with 1% osmium tetroxide (0.1 M,
pH 7.2), dehydrated in a graded series of ethanol
(70%, 80%, 90% and 100%), cleared in toluene
and embedded in Epon812 for 24h at 60oC. Semi-
thin sections of 1 µm were cut, stained with tolui-
dine blue and viewed with the light microscope for
proper orientation. Tissues were then thin sectioned
(60 nm), stained with uranyl acetate and lead citrate
and evaluated in a JEOL 1200 SX transmission elec-
tron microscope [18]. 
Serum TNF-α measurement
Blood samples were taken intra-cordially in dry
tubes. After centrifugation, serum was aspirated and
TNF-α was measured with the ELISA method
(Biosource Rat TNF-α kit, CA, USA). TNF-α meas-
urement level was 0-1000 pg/ml. 
Statistical analysis
All data were analyzed using the SPSS program ver-
sion 13.0. The results were expressed as mean ±
standard error (SE). Kruskall-Wallis test was used for
statistical comparison of the groups and a p < 0.05
was considered as statistically significant.
RESULTS
We found dilatation in alveolar duct and respiratory
bronchioles, proliferation of alveolar epithelial
cells, inflammatory cell infiltration and vascular
congestion in the MON control and COPD control
groups. The number of type 2 pneumocyte cells and
surfactant levels was increased in electron micro-
scope specimens of both groups (Figures 1 and 2). 
In the MON group, on the other hand, dilatation of
alveolar duct was seen less prominently, and there
was a decrease in the inflammatory cell infiltration,
respiratory epithelial cell proliferation and vascular
congestion (Figure 3). 
Electron microscopic findings were found to be less
improved with montelukast therapy where surfac-
tant deposition and an increase in the number of
macrophages were observed (Figure 4). 
The total histopathological score was significantly
lower in the healthy control group (2.3 ± 0.2) com-
pared to COPD control and MON control groups 
(p < 0.001). However, there was also a significant
difference between the montelukast group (MON)
and both COPD controls and MON controls (5.1 ±
0.6 in MON vs. 8.4 ± 0.6 in MON controls and 8.7
± 0.4 in COPD controls, p < 0.05). There was no
significant difference between the healthy control
group and the MON group (Figure 5). 
All four categories included in the total histopatho-
logical score were also evaluated separately (Table
I). We found the inflammatory cell infiltration, res-
piratory epithelial proliferation and respiratory tract
dilatation to be decreased in the smoke-exposed rat
lungs of the montelukast group compared to the
MON control and COPD control groups. Vascular
congestion was found to be less affected by the
montelukast treatment. 
Smoke exposure caused a significant elevation of
serum TNF-α levels in COPD controls and MON
controls. However montelukast decreased this ele-
vation to a level comparable with the healthy con-
trols; no significant difference was found between
the montelukast group and healthy controls (38.84
± 4.9 pg/ml vs. 29.5 ± 3.6 pg/ml respectively, 
p > 0.05) (Figure 6).
DISCUSSION 
This study demonstrated that montelukast has pro-
tective effects on both inflammatory and
histopathological aspects of smoke-induced lung
FIGURE 1: LIGHT MICROSCOPIC FINDINGS OF LUNG TISSUE
FROM MONTELUKAST (MON) CONTROL GROUP 
Evidence can be seen of (1a) alveolar duct dilatation (*), respiratory
epithelial proliferation (→), and (1b) increased inflammatory cell
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injury. The effects of smoke exposure in the lung
parenchyma was evaluated with light and electron
microscopes and montelukast was found to de-
crease the inflammatory cell infiltration, respiratory
cell proliferation, and alveoli-bronchiolar dilatation
in smoke-exposed rat lungs. The effects on surfac-
tant deposition and macrophage recruitment in the
alveolar space were less prominent; however serum
TNF-α levels were shown to be suppressed signifi-
cantly with montelukast treatment. 
Smoke-induced increase in leukotriene levels and
associated changes in the airways such as recruit-
ment of inflammatory cells, vascular congestion,
mucus hypersecretion and bronchoconstriction
have been shown previously [1,19,20]. In addition,
our study displayed significant alveolar dilatation,
inflammatory cell infiltration, vascular congestion
and surfactant deposition in the smoke exposed rat
lung and indicated some beneficial effects of mon-
telukast on such alterations.
Yüksel et al. investigated the effects of montelukast
on smoke-induced lung injury in rats [14]. They per-
formed morphometric examinations of lung tissues
and counted mast cell numbers in lung parenchyma
besides histopathological evaluation. Using a digi-
tal computerized system adapted to a light micro-
scope, they measured linear intercept of alveolar
septa as an indicator of airspace dilatation and vol-
ume density of alveolar septa and the density of
alveolar surface area as indicators of tissue loss.
Smoke exposure was found to be associated with
alveolar dilatation and tissue loss though significant
improvements were noted in the montelukast treat-
ed rats. The authors also reported that histopatho-
logical alterations such as airspace enlargements,
alveolar distortion and visceral pleural thickening
were more severe in the smoke-exposed controls
than in the montelukast treated group [14]. In our
study, a histopathological scoring system was used
to evaluate lung parenchyma and, although the
methods are not quite the same as those in the study
of Yüksel et al., we also demonstrated several protec-
tive effects of montelukast on smoke-induced lung
injury. In addition, we found a significant decrease
in the serum levels of TNF-α in the montelukast
treated rats. 
TNF-α which is known as a neutrophil chemotactic
cytokine has been found to be elevated in human
FIGURE 2: LIGHT AND ELECTRON MICROSCOPIC FINDINGS
OF COPD CONTROL GROUP 
b
a
2a: showing inflammatory cell infiltration (►) and airway wall
edema (o) (H&E, X100). 2b: showing increase in surfactant deposi-
tion (→) and increase in the number of macrophages (►) (X6000).
FIGURE 3: LIGHT MICROSCOPIC EVALUATION OF LUNG
TISSUE FROM MONTELUKAST GROUP (MON)
b
a
3a: showing alveolar duct dilatation (*) and decrease in respiratory
epithelial proliferation (→). 3b: showing decrease in inflammatory 































smokers and it is thought to have an important role
in the pathogenesis of COPD since animal models
of smoke exposure showed a strong correlation be-
tween serum TNF-α levels and airspace dilatation
[21]. 
Montelukast has been shown to inhibit several pro-
inflammatory cytokines in animal models of asthma
[12,13]. Maeba et al. reported an inhibitory effect
of montelukast on the lipopolysaccharide induced
production of IL-1β, IL-6, TNF-α and MCP-1 from pe-
ripheral blood mononuclear cells, while Can et al.
showed a decrease in serum TNF-α levels in pediatric
asthmatics with montelukast treatment [22,23]. Our
study demonstrated the inhibitory effect of mon-
telukast on smoke-induced elevation of serum TNF-α
in rats. This finding suggests that, besides its anti-in-
flammatory effects in asthma, montelukast might also
suppress smoke induced inflammation. 
Recent studies have reported that smoking may af-
fect the response to anti-inflammatory therapy since
smoker asthmatics get less benefit from treatment
with inhaled corticosteroid, and have recommend-
ed leukotriene antagonists as an alternative anti-in-
flammatory agent in the treatment of smoker asth-
matics [8]. 
On the other hand, COPD has a distinct association
with smoking and is thought to have different in-
flammatory characteristics from asthmatics. The
bronchodilator effects of leukotriene modifiers have
been investigated in clinical studies of COPD and
FIGURE 4: ELECTRON PHOTOMICROGRAPH OF LUNG TISSUE



















* p < 0.05; MON group vs. MON control 
and COPD control groups. 
** p < 0.001; healthy controls vs. MON control 












FIGURE 5: HISTOPATHOLOGICAL SCORE OF THE LUNG
TISSUE SPECIMEN
TABLE I: HISTOPATHOLOGICAL SCORE FOR SINGLE PARAMETERS AND TOTAL SCORE  
Groups
Histopathological categories Grade range Healthy control MON group MON control COPD control
Dilatation of respiratory tract 0-3 0.7 ± 0.2 1.7 ± 0.2 2.3 ± 0.3 2.3 ± 0.3
Infiltration of inflammatory cells 0-3 0.6 ± 0.2 1.3 ± 0.2 2.9 ± 0.1 2.9 ± 0.1
Proliferation of respiratory epithelium 0-3 0.9 ± 0.1 1.4 ± 0.2 2.6 ± 0.2 2.7 ± 0.2
Vascular congestion 0-1 0.1 ± 0.1 0.7 ± 0.2 0.7 ± 0.2 0.9 ± 0.1
Total histopathological score 0-10 2.3 ± 0.2** 5.1 ± 0.6* 8.4 ± 0.6 8.7 ± 0.4
* p< 0.05; MON group vs. MON control and COPD control groups. 
** p< 0.001; healthy control vs. MON control and COPD control groups. 
4a showing: increase in surfactant deposition in the type 2 pneu-
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improvements in FEV1 levels were reported [9-11].
Montelukast was also shown to be associated with
symptom relief, improvements in the quality of life
scores, decrease in the use of inhaled cortico -
steroids and bronchodilators, and a reduction in ex-
acerbations and hospitalization rates [9,24]. 
However data are limited about the anti-inflamma-
tory effects of montelukast in smoke-induced in-
flammation. Celik et al. studied the effects of mon-
telukast on pulmonary function tests and quality of
life scores in COPD patients; in this controlled
study sputum samples were also obtained for the
evaluation of inflammation, which it was possible
to examine in 24 patients. Compared to the control
group, a significant decrease in neutrophilic inflam-
mation was observed in the montelukast treated
group [9]. Although we did not count an exact
number of inflammatory cells, our study also
demonstrated a significant decrease in inflammato-
ry cell infiltration in the lung parenchyma and a re-
duction in serum TNF-α, which is thought to be an
indicator of neutrophilic inflammation.
There are some limitations of our study as a model
of airway inflammation; one may be the lack of in-
flammatory marker levels in bronchial secretions
and the other may be the lack of differential inflam-
matory cell counts. Nevertheless, we thought that
serum levels of TNF-α is an important marker for in-
flammation in COPD and demonstrating its reduc-
tion with montelukast therapy is quite an interesting
finding. 
In conclusion, treatment with montelukast in
smoke-exposed rats is shown to be associated with
the suppression of serum TNF-α levels as well as
with improvements in histopathological alterations
incurred by smoke exposure. Further studies are
needed to investigate the use of montelukast as an
anti-inflammatory agent in smoke-induced lung dis-
eases. 
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*p < 0.01; healthy control vs. MON control 
and COPD control groups.
** p < 0.05; MON group vs. MON control 









FIGURE 6: SERUM TNF-α LEVELS OF STUDY GROUPS 
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